Proniras Corporation is a preclinical-stage biotech company focused on development of a new parenteral medical countermeasure (MCM) to treat seizures and brain injury that occurs following exposure to organophosphorus nerve agents.
Location: United States, Washington, Seattle
Employees: 1-10
Total raised: $89.5M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | WRF Capita... | wrfseattle... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 27.04.2018 | - | $89.5M | - |
Mentions in press and media 7
| Date | Title | Description |
| 01.02.2024 | Proniras Lands $4.65M Series B Financing | SEATTLE, WA, Proniras today announced the successful completion of a $4.65 million funding round. >> Click here for more funding data on Proniras >> To export Proniras funding data to PDF and Excel, click here Proniras Co... |
| 01.02.2024 | Proniras Secures $4.65 in Series B Financing | Proniras, a Seattle, WA-based clinical-stage biotechnology company developing novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system disorders, raised $4.65M in Series B funding. The round ... |
| 27.04.2018 | Proniras launches with BARDA funding to pit migraine drug against nerve agents | Accelerator Life Science Partners launched a spinoff company to develop an investigational migraine drug for a variety of seizure disorders and landed a federal contract to explore its use as a medical countermeasure against the effects of ... |
| 27.04.2018 | Proniras Corp. launches in Seattle, scores $89.5 million contract to develop new seizure drug | Chris Toombs, Proniras co-founder and chief scientific officer. (Accelerator Life Science Partners Photo) Accelerator Life Science Partners, a Seattle-based life sciences investment fund and umbrella company, unveiled its newest company wit... |
| 27.04.2018 | Proniras launches with BARDA funding to pit migraine drug against nerve agents | Accelerator Life Science Partners launched a spinoff company to develop an investigational migraine drug for a variety of seizure disorders and landed a federal contract to explore its use as a medical countermeasure against the effects of ... |
| - | Proniras Corp | “Proniras” |
| - | Proniras: $4.65 Million Funding Raised To Develop Small-Molecule Therapeutics For Substance Use Treatment | Proniras Corporation – a clinical-stage biotechnology company developing novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system disorders – announced the successful completion of a $4.65 mi... |